The overall goal of this proposal is to discover molecules along trafficking pathways leading to the convergence of two key proteins in Alzheimer's disease (AD) pathogenesis - Amyloid Precursor Protein (APP) and ?-site APP-cleaving enzyme-1 (BACE-1). This convergence, and consequent enzymatic ?-cleavage of APP, is the rate-limiting step of amyloid beta (A?) production - a pathological hallmark of AD brains and a prevailing focus in AD research. Visualizing APP/BACE-1 trafficking in hippocampal neurons, we recently found that after synthesis, APP and BACE-1 are sorted into distinct vesicles, with BACE-1 selectively routed into recycling endosomes. At steady state, APP and BACE-1 convergence is a low-frequency event - producing A? at basal levels (Das et al., Neuron 2013; PMID: 23931995). Following up on these studies, we reasoned that ascertaining molecular pathways leading up-to this seminal convergence event would allow: 1) identification of the repertoire of trafficking pathways by which APP and BACE-1 meet to initiate the amyloidogenic cascade; and 2) discovery of novel druggable targets that can be manipulated to diminish APP/BACE-1 convergence and A? production. Towards this we developed an in-cellulo Optical assay to visualize Convergence of APP and BACE-1 (OptiCAB). Based on fluorescence complementation, this assay reports APP/BACE-1 interactions as a simple on/off readout, correlates with APP ?-cleavage, and is suitable for large-scale analyses. Combining this assay with a newly-developed powerful genome-scale screen using CRISPR-Cas9 knockout (GeCKO) library (collaboration with Feng Zhang, MIT), our goal is to discover genes involved in `trafficking-related' upstream pathways that eventually lead to APP/BACE-1 convergence and A? production. Notably, CRISPR-Cas9- based screens are not limited by incomplete protein depletion and confounding off-target effects that have historically limited the utility of RNAi. Secondary validation of `hits' (i.e. genes that attenuate APP/BACE-1 interactions) will be done in human induced pluripotent stem cells (iPSC's); where APP-cleavage products will be analyzed after relevant CRISPR-knockout.
Our aims are:
Aim #1 : Discover pathways leading to APP and BACE-1 convergence using OptiCAB and GeCKO;
and Aim #2 : Validate `hits' from Aim 1 in human neuronally-differentiated iPSCs. Our experiments will not only provide insights into the physiologic amyloid-pathway in humans, but may also offer new targets for AD. Finally, note that our focus on the repertoire of trafficking pathways leading up-t APP/BACE-1 approximation stems from our own live-imaging studies; and is different from the current narrow focus on enzymatic activity of the secretases.
Cleavage of APP (substrate) by BACE-1 (enzyme) is the rate-limiting step in amyloid-beta production - a major pathologic feature of Alzheimer's disease; and physical approximation of this substrate/enzyme pair is an obvious prerequisite for APP cleavage. We have developed a new optical assay to visualize APP/BACE-1 approximation in cells (called OptiCAB). Combining this optical assay with a human genome scale CRISPR-Cas9-based screen developed recently (called GeCKO); our aim is to discover genes involved in trafficking (and related) upstream pathways that eventually lead to APP/BACE-1 interaction (and subsequent APP cleavage).
|Sun, Jichao; Roy, Subhojit (2018) The physical approximation of APP and BACE-1: A key event in alzheimer's disease pathogenesis. Dev Neurobiol 78:340-347|
|Roy, Subhojit (2017) Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease. Nat Neurosci 20:1514-1515|
|Leterrier, Christophe; Dubey, Pankaj; Roy, Subhojit (2017) The nano-architecture of the axonal cytoskeleton. Nat Rev Neurosci 18:713-726|